Skip to Content
  1. Authors
  2. Stefan Quenneville, CFA

Stefan Quenneville, CFA

Stefan Quenneville, CFA, is an equity analyst for Morningstar.

Latest

Some high-quality biotech names are trading at substantial discounts, as the market reacts to near-term concerns over pricing and biosimilar competition.

Regeneron's moat is widening thanks to recent clinical successes and a productive pipeline; however, investors should wait for a better price before buying.